We have located links that may give you full text access.
Nadir CD4 is negatively associated with antinuclear antibody detection in HCV/HIV coinfected patients.
Journal of Acquired Immune Deficiency Syndromes : JAIDS 2018 December 13
BACKGROUND: HCV and HIV infections are associated with higher risk of autoimmune diseases and T-cell dysfunction.
SETTING: We evaluate prevalence and factors associated with the presence of autoimmune antinuclear (ANA), anti-smooth muscle actin (aSMA) and anti-liver kidney microsomes (aLKM1) antibodies (Ab) in HCV/HIV coinfected patients during the post-cART era.
METHODS: cross-sectional observational study, nested in the ANRS CO13 HEPAVIH cohort (NCT number: NCT03324633). We selected patients with both ANA testing and T-cell immunophenotyping determination during the cohort follow-up and collected aLKM1 and aSMA data when available. Logistic regression models were built to determine factors associated with the presence of auto-Ab.
RESULTS: 223 HCV/HIV coinfected patients fulfilled selection criteria. Prevalence of ANA and aSMA was 43.5% and 23.2%, respectively, and both were detected in 13.3% of patients. Isolated aSMA were detected in 9.9% and aLKM1 in 2 patients. In multivariable analysis, only a low nadir CD4 T-cell count was significantly associated with ANA detection.
CONCLUSION: ANA and aSMA detection remain frequent in HCV/HIV coinfected patients during post-cART era despite fair immune restoration. These results advocate for a close monitoring of ANA before immune checkpoint inhibitor therapy in these patients with greater caution for those with a low nadir CD4 T- cell count.
SETTING: We evaluate prevalence and factors associated with the presence of autoimmune antinuclear (ANA), anti-smooth muscle actin (aSMA) and anti-liver kidney microsomes (aLKM1) antibodies (Ab) in HCV/HIV coinfected patients during the post-cART era.
METHODS: cross-sectional observational study, nested in the ANRS CO13 HEPAVIH cohort (NCT number: NCT03324633). We selected patients with both ANA testing and T-cell immunophenotyping determination during the cohort follow-up and collected aLKM1 and aSMA data when available. Logistic regression models were built to determine factors associated with the presence of auto-Ab.
RESULTS: 223 HCV/HIV coinfected patients fulfilled selection criteria. Prevalence of ANA and aSMA was 43.5% and 23.2%, respectively, and both were detected in 13.3% of patients. Isolated aSMA were detected in 9.9% and aLKM1 in 2 patients. In multivariable analysis, only a low nadir CD4 T-cell count was significantly associated with ANA detection.
CONCLUSION: ANA and aSMA detection remain frequent in HCV/HIV coinfected patients during post-cART era despite fair immune restoration. These results advocate for a close monitoring of ANA before immune checkpoint inhibitor therapy in these patients with greater caution for those with a low nadir CD4 T- cell count.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app